All News

Findings from the phase 3 KEYNOTE-A18 trial support the supplemental biologics license application for a pembrolizumab-based regimen as a treatment for patients with newly diagnosed, high-risk, locally advanced cervical cancer.

Arvind N. Dasari, MD, and Cathy Eng, MD, gave an overview on the use of fruquintinib in colorectal cancer.

Adding all-trans retinoic acid to non-intensive chemotherapy appears to produce higher toxicity in elderly unfit patients with acute myeloid leukemia harboring NPM1 mutations.

Data from the phase 3 LITESPARK-005 trial support the supplemental new drug application for belzutifan as a treatment for patients with advanced renal cell carcinoma.

KT-333 is under investigation as a treatment for adult patients with relapsed/refractory lymphomas, leukemias, and solid tumors in a phase 1 clinical trial.

Objective response rate appears to be numerically higher for patients receiving zanubrutinib for relapsed/refractory mantle cell lymphoma in the second-line setting than in later lines of treatment.

Investigators of the phase 1b/2 KontRASt-01 trial will continue their evaluation of TNO155 plus JDQ433 in KRAS G12C-mutated solid tumors as part of an expansion portion of the trial.

Thomas G. Martin, MD, discussed with his colleagues cytokine release syndrome after treatment with teclistamab for patients with multiple myeloma.

Findings from the phase 2 ALYCANTE trial support axicabtagene ciloleucel as a second-line treatment for patients with relapsed/refractory large B-cell lymphoma who are ineligible to undergo a transplant.

Data from a previous MPN LANDMARK survey highlight that many patients with polycythemia vera experience symptoms that lead to reduced quality of life.

Responses in patients with hormone receptor–positive, HER2-mutated breast cancer who crossed over to receive neratinib plus fulvestrant and trastuzumab support the necessity of neratinib in the triplet regimen.

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Treatment with zongertinib produces low rates of EGFR-mediated adverse effects among patients with HER2-mutated non–small cell lung cancer in the phase 1a/b BEAMION Lung-1 trial.

Robert Motzer, MD, led an expert panel to discuss the phase 3 CONTACT-03 which examined patients with renal cell carcinoma.

Baseline characteristics do not appear to correlate with long-term benefits for patients receiving durvalumab plus tremelimumab and chemotherapy for metastatic non–small cell lung cancer in the phase 3 POSEIDON trial.

Ryan Jacobs, MD, and Alan Pierre Zausner Skarbnik, MD, discussed the use of acalabrutinib and zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

With the approval of momelotinib by the FDA, the updated use for its role in myelofibrosis will potentially change clinical practice, according to Ruben Mesa, MD.

Patients with myelofibrosis and anemia can now receive treatment with momelotinib following the agent’s approval by the FDA based on results from the phase 3 MOMENTUM trial.

Investigators report no differences in progression-free survival among patients with nonseminomatous testicular cancer who received surveillance or adjuvant chemotherapy in a cohort study.

Findings from the phase 3 AEGEAN trial suggest that patients with EGFR-mutated non–small cell lung cancer experience similar outcomes whether receiving durvalumab or placebo.

Data from the phase 2 JACKPOT8 PARTB study support the new drug application for golidocitinib as a treatment for relapsed/refractory peripheral T-cell lymphoma in China.

CancerNetwork hosted a Training Academy focused on sequencing therapies for patients with multiple myeloma who are treated with bispecific antibodies.

The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.

Across several clinical trials, Unfold AI appears to help in prostate cancer treatment selection and follow-up.

Prescribing information has been updated to include temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma or refractory anaplastic astrocytoma.

Treatment with adagrasib appears to be particularly well tolerated in patients with KRAS G12C–mutated non–small cell lung cancer who receive it for more than 1 year.

Data from a phase 1/2 trial support the fast track designation for tulmimetostat as a treatment for patients with ARID1A-mutated advanced, recurrent or metastatic endometrial cancer.

Iruplinalib appears tolerable with no new safety signals among patients with locally advanced and metastatic ALK-positive non–small cell lung cancer in the phase 3 INSPIRE trial.

Co-editor-in-chief, Howard S. Hochster, MD, reviews the ongoing drug price negotiations and the effect it will have in the health care space.

Data from the phase 2 EVOKE-02 trial support further assessment of sacituzumab govitecan plus pembrolizumab as a frontline treatment for metastatic non–small cell lung cancer.